Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge

Diagnostic Pathology

Anil V Parwani³  Marie B Acquafondata²  Kathy M Cieply¹  Matthew A Smith²  Somak Roy² 

[1] Florescence in-situ hybridization research and development laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA, 15232, USA;Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15232, USA;Division of Pathology Informatics, Department of Pathology, 5230 Centre Avenue, Room WG 07, Pittsburgh, PA, 15232, USA

关键词: E-cadherin;    Beta-catenin;    Colorectal;    Metastatic;    Primary;    Adenocarcinoma;    Bladder;   

Others  :  807877
DOI  :  10.1186/1746-1596-7-151

 received in 2012-09-28, accepted in 2012-10-22,  发布年份 2012

【 摘 要 】

Aim

This study attempted to distinguish primary bladder adenocarcinoma (PBA) from metastatic colonic adenocarcinomas (MCA), which is a difficult diagnostic and clinical problem.

Methods

Twenty-four cases of bladder adenocarcinomas (12 primary & 12 metastatic colorectal) were included in the study with urothelial carcinoma (UC) and colonic adenocarcinoma (CA) as controls. A panel of immunohistochemical (IHC) stains along with fluorescence in-situ hybridization (FISH), using the UroVysion probe set, was performed.

Results

The majority of the PBAs presented with advanced disease. Enteric histologic subtype was the most common morphological variant. Strong nuclear with cytoplasmic-membranous staining of β-catenin was seen in 75% of MCA and only 16.7% PBA (<10% staining cells). Although abnormal nuclear staining with E-cadherin was seen in both PBA and MCA, it was more frequent in former. CK-7, CK-20, villin and CDX-2 stains were not helpful in distinguishing the two entities. FISH did not reveal any unique differences in chromosomal abnormality between the two groups.

Conclusion

Although there was a statistically significant difference in β-catenin and E-cadherin staining between two groups, we did not find any IHC or FISH marker that was specific for PBA. Distinction between PBA and MCA remains a diagnostic problem and clinical correlation is vital before rendering a diagnosis.

Virtual slides

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1393156268152357 webcite

【 授权许可】

   
2012 Roy et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG: Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991, 67:2165-2172.
• [2]Thomas AA, Stephenson AJ, Campbell SC, Jones JS, Hansel DE: Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol 2009, 40:108-116.
• [3]Wang HL, Lu DW, Yerian LM, Alsikafi N, Steinberg G, Hart J, Yang XJ: Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001, 25:1380-1387.
• [4]Anderstrom C, Johansson SL, von Schultz L: Primary adenocarcinoma of the urinary bladder. A clinicopathologic and prognostic study. Cancer 1983, 52:1273-1280.
• [5]Jones WA, Gibbons RP, Correa RJ Jr, Cummings KB, Mason JT: Primary adenocarcinoma of bladder. Urology 1980, 15:119-122.
• [6]Nocks BN, Heney NM, Daly JJ: Primary adenocarcinoma of urinary bladder. Urology 1983, 21:26-29.
• [7]Epstein JI, Amin MB, Reuter VE: Glandular lesions. Philadelphia: Lippincott Williams & Wilkins; 2004.
• [8]Melicow MM: Tumors of the urinary bladder: a clinico-pathological analysis of over 2500 specimens and biopsies. J Urol 1955, 74:498-521.
• [9]Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE: Malignant urachal lesions. J Urol 1984, 131:1-8.
• [10]Mostofi FK, Thomson RV, Dean AL Jr: Mucous adenocarcinoma of the urinary bladder. Cancer 1955, 8:741-758.
• [11]Abol-Enein H, el Mekresh MM, el Baz MA, Abol-Enein H, Ghoneim MA: Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol 1998, 82:206-212.
• [12]Shaaban AA, Elbaz MA, Tribukait B: Primary nonurachal adenocarcinoma in the bilharzial urinary bladder: deoxyribonucleic acid flow cytometric and morphologic characterization in 93 cases. Urology 1998, 51:469-476.
• [13]Sung MT, Lopez-Beltran A, Eble JN, MacLennan GT, Tan PH, Montironi R, Jones TD, Ulbright TM, Blair JE, Cheng L: Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol 2006, 19:1395-1401.
• [14]Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 2009, 33:659-668.
• [15]Raspollini MR, Nesi G, Baroni G, Girardi LR, Taddei GL: Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. Appl Immunohistochem Mol Morphol 2005, 13:358-362.
• [16]Suh N, Yang XJ, Tretiakova MS, Humphrey PA, Wang HL: Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005, 18:1217-1222.
• [17]Tamboli P, Mohsin SK, Hailemariam S, Amin MB: Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel. Arch Pathol Lab Med 2002, 126:1057-1063.
• [18]Del Sordo R, Bellezza G, Colella R, Mameli MG, Sidoni A, Cavaliere A: Primary signet-ring cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 5 cases. Appl Immunohistochem Mol Morphol 2009, 17:18-22.
• [19]Chung DC: The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000, 119:854-865.
• [20]Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
• [21]Elston MS, Gill AJ, Conaglen JV, Clarkson A, Cook RJ, Little NS, Robinson BG, Clifton-Bligh RJ, McDonald KL: Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Endocrinol Metab 2009, 94:1436-1442.
• [22]Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RJ, Wheeler TM, Lerner SP: E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001, 165:1473-1479.
• [23]Chetty R, Serra S, Asa SL: Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol 2008, 32:413-419.
• [24]Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R, Woodgett JR: Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol 2008, 21:271-281.
• [25]Werling RW, Yaziji H, Bacchi CE, Gown AM: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003, 27:303-310.
• [26]Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J: Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol 2008, 130:552-559.